SG11201809501PA - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide - Google Patents
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideInfo
- Publication number
- SG11201809501PA SG11201809501PA SG11201809501PA SG11201809501PA SG11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA SG 11201809501P A SG11201809501P A SG 11201809501PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- chlorophenyl
- street
- pct
- san diego
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 2
- 201000005787 hematologic cancer Diseases 0.000 title abstract 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title abstract 2
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101150015280 Cel gene Proteins 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101111111101011111001111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/214014 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: Stevenson Street, San Francisco, CA 94103 (US). POUR- A61K 31/454 (2006.01) A61P 35/02 (2006.01) DEHNAD, Michael; 3972 26th Street, San Francisco, CA (21) A61K 31/4545 (2006.01) 94131 (US). RAPPLEY, Irit; 2645 Gobat Avenue, San Diego, CA 92122 (US). International Application Number: PCT/US2017/035892 (74) Agent: BHUMRALKAR, Megha et al.; Jones Day, 250 (22) International Filing Date: Vesey Street, New York, NY 10281-1047 (US). 05 June 2017 (05.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/346,344 06 June 2016 (06.06.2016) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: CELGENE CORPORATION [US/US]; 86 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Morris Avenue, Summit, NJ 07901 (US). PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (72) Inventors: CARRANCIO, Soraya; 5205 Fiore Terrace, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Apt. B419, San Diego, CA 92122 (US). HOLLENBACH, Paul; 20793 Gleenwood Drive, Castro Valley, CA 94552 (84) Designated States (unless otherwise indicated, for every — (US). LOPEZ-GIRONA, Antonia; 8959 January Place, kind of regional protection available): ARIPO (BW, GH, San Diego, CA 92122 (US). MACBETH, Kyle; 1356 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = = (54) Title: TREATMENT OF A HEMATOLOGIC MALIGNANCY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPI _ _ PERIDIN-3-YL)-1-0X0ISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE _ = Counts FamA = = = 0 _ = = = 0 = 1 l Fain C 1000 = = _ = = = = 15C0 ' — 1tI = T -- T T - r - T - T - r - I TT I T T\" T T Y T T \"T\" T ri \"I T T 1 T - T - 1\" T - 1\" - 7 .- I T 7 . T - 3 - 7 - 1 ---- r - r - _ 0 20 30 1-1 P nihata] Copper (CO 7r 11 0 FIG. 1 71- 1-1 ei ---- (57) : Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic IN syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-y1)-1-oxoisoindolin-5-yOmethyl)-2,2-difluoroac © etamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, N co -crystal, clathrate, or polymorph thereof to a patient. O [Continued on next page] WO 2017/214014 Al MIDEDIMOMOIDEIRMEM0011010HOIROEHIMEMOIS UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346344P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/035892 WO2017214014A1 (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809501PA true SG11201809501PA (en) | 2018-12-28 |
Family
ID=60482040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809501PA SG11201809501PA (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10245258B2 (en) |
| EP (1) | EP3463358A4 (en) |
| JP (1) | JP7163281B2 (en) |
| KR (1) | KR20190015300A (en) |
| CN (2) | CN115282149A (en) |
| AU (2) | AU2017278114B2 (en) |
| BR (1) | BR112018075206A2 (en) |
| CA (1) | CA3026396A1 (en) |
| CL (1) | CL2018003499A1 (en) |
| EA (1) | EA201892746A1 (en) |
| IL (1) | IL262565B (en) |
| MX (1) | MX388717B (en) |
| SG (1) | SG11201809501PA (en) |
| WO (1) | WO2017214014A1 (en) |
| ZA (1) | ZA201807105B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
| RS64976B1 (en) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| CN113347974A (en) * | 2018-12-31 | 2021-09-03 | 细胞基因公司 | Compositions and methods of use of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide |
| KR20220054347A (en) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | Method of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US11583536B2 (en) | 2019-10-21 | 2023-02-21 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| KR20220110494A (en) * | 2019-11-05 | 2022-08-08 | 셀진 코포레이션 | 2-(4-Chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoro Combination therapy with acetamide |
| CA3158942A1 (en) | 2019-12-06 | 2021-06-10 | Marie G. Beauchamps | Processes for preparing 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AU2021239822A1 (en) * | 2020-03-16 | 2022-10-13 | Celgene Corporation | Combination therapy for acute myeloid leukemia |
| JP2023541434A (en) * | 2020-09-14 | 2023-10-02 | アルビナス・オペレーションズ・インコーポレイテッド | Crystalline Forms of Compounds for Targeted Degradation of Estrogen Receptors |
| MX2023003114A (en) | 2020-09-23 | 2023-03-23 | St Jude Childrens Res Hospital Inc | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)arylsulfonamide analogs as modulators of cereblon protein. |
| KR20240066906A (en) * | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | Isoindolinone compounds with substituted quinoline amide and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005515996A (en) * | 2001-12-03 | 2005-06-02 | ノバセア インコーポレイティッド | Pharmaceutical composition comprising active vitamin D compound |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20090175869A1 (en) * | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| MX2011012330A (en) | 2009-05-20 | 2011-12-16 | Hybrigenics Sa | New therapeutical uses of inecalcitol. |
| HK1200716A1 (en) * | 2011-11-01 | 2015-08-14 | 细胞基因公司 | Method for treating cancer using an oral preparation of a cytidine analog |
| LT3077004T (en) | 2013-12-05 | 2020-05-11 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP6871256B2 (en) * | 2016-01-08 | 2021-05-12 | セルジーン コーポレイション | 2- (4-Chlorophenyl) -N-((2- (2,6-dioxopiperidine-3-yl) -1-oxoisoindoline-5-yl) methyl) -2,2-difluoroacetamide preparation |
| EP3399981B1 (en) | 2016-01-08 | 2023-08-02 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| PL3399978T3 (en) | 2016-01-08 | 2021-04-06 | Celgene Corporation | Antiproliferative compounds, and their pharmaceutical compositions and uses |
-
2017
- 2017-06-05 IL IL262565A patent/IL262565B/en unknown
- 2017-06-05 US US15/614,434 patent/US10245258B2/en active Active
- 2017-06-05 CA CA3026396A patent/CA3026396A1/en active Pending
- 2017-06-05 AU AU2017278114A patent/AU2017278114B2/en active Active
- 2017-06-05 EA EA201892746A patent/EA201892746A1/en unknown
- 2017-06-05 SG SG11201809501PA patent/SG11201809501PA/en unknown
- 2017-06-05 WO PCT/US2017/035892 patent/WO2017214014A1/en not_active Ceased
- 2017-06-05 JP JP2019516086A patent/JP7163281B2/en active Active
- 2017-06-05 EP EP17810774.4A patent/EP3463358A4/en not_active Withdrawn
- 2017-06-05 CN CN202211003162.1A patent/CN115282149A/en active Pending
- 2017-06-05 KR KR1020187035780A patent/KR20190015300A/en not_active Ceased
- 2017-06-05 MX MX2018015120A patent/MX388717B/en unknown
- 2017-06-05 CN CN201780035323.6A patent/CN109414436A/en active Pending
- 2017-06-05 BR BR112018075206-1A patent/BR112018075206A2/en not_active Application Discontinuation
-
2018
- 2018-10-24 ZA ZA2018/07105A patent/ZA201807105B/en unknown
- 2018-12-06 CL CL2018003499A patent/CL2018003499A1/en unknown
-
2019
- 2019-02-13 US US16/275,234 patent/US20190175573A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,267 patent/US11590117B2/en active Active
-
2023
- 2023-01-25 US US18/101,499 patent/US20230158009A1/en not_active Abandoned
- 2023-04-06 AU AU2023202159A patent/AU2023202159A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019517587A (en) | 2019-06-24 |
| US20230158009A1 (en) | 2023-05-25 |
| IL262565A (en) | 2018-12-31 |
| CA3026396A1 (en) | 2017-12-14 |
| US10245258B2 (en) | 2019-04-02 |
| MX2018015120A (en) | 2019-04-15 |
| US11590117B2 (en) | 2023-02-28 |
| CL2018003499A1 (en) | 2019-03-15 |
| CN109414436A (en) | 2019-03-01 |
| KR20190015300A (en) | 2019-02-13 |
| US20190175573A1 (en) | 2019-06-13 |
| AU2023202159A1 (en) | 2023-05-04 |
| BR112018075206A2 (en) | 2019-03-19 |
| MX388717B (en) | 2025-03-20 |
| CN115282149A (en) | 2022-11-04 |
| US20210154182A1 (en) | 2021-05-27 |
| US20170348298A1 (en) | 2017-12-07 |
| AU2017278114A1 (en) | 2018-11-29 |
| EP3463358A1 (en) | 2019-04-10 |
| WO2017214014A1 (en) | 2017-12-14 |
| IL262565B (en) | 2022-08-01 |
| EA201892746A1 (en) | 2019-06-28 |
| ZA201807105B (en) | 2020-01-29 |
| EP3463358A4 (en) | 2020-07-22 |
| JP7163281B2 (en) | 2022-10-31 |
| AU2017278114B2 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809501PA (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201901937WA (en) | Pyridine compound | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805777QA (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201908228TA (en) | Chemical compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201804100UA (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| SG11201810793XA (en) | Pharmaceutical combinations |